These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25993204)

  • 1. Beyond "second-line" in non-small cell lung cancer: therapy and supportive care.
    Martins RG; Reynolds CH; Riely GJ
    Am Soc Clin Oncol Educ Book; 2015; ():e414-8. PubMed ID: 25993204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Best supportive care versus palliative chemotherapy in nonsmall-cell lung cancer.
    Medley L; Cullen M
    Curr Opin Oncol; 2002 Jul; 14(4):384-8. PubMed ID: 12130920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy versus best supportive care for advanced non-small-cell lung cancer.
    Abang AM
    Am J Health Syst Pharm; 1996 Dec; 53(24):2980-4. PubMed ID: 8974162
    [No Abstract]   [Full Text] [Related]  

  • 4. Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview.
    Genestreti G; Grossi F; Genova C; Burgio MA; Bongiovanni A; Gavelli G; Bartolotti M; Di Battista M; Cavallo G; Brandes AA
    Future Oncol; 2014 Oct; 10(13):2081-96. PubMed ID: 25396779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment algorithm in 2014 for advanced non-small cell lung cancer: therapy selection by tumour histology and molecular biology.
    Manegold C
    Adv Med Sci; 2014 Sep; 59(2):308-13. PubMed ID: 25240504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From best supportive care to early palliative care.
    Klastersky J
    Curr Opin Oncol; 2011 Jul; 23(4):311-2. PubMed ID: 21505337
    [No Abstract]   [Full Text] [Related]  

  • 7. What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.
    Lester JF; Agulnik J; Akerborg O; Chouaid C; De Geer A; Finnern HW; Herder GJ; Lungershausen J; Mitchell PL; Vansteenkiste J; Ziske C; Goker E
    Lung Cancer; 2013 Oct; 82(1):128-35. PubMed ID: 23910909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for stage IV non-small cell lung cancer.
    Bitran JD; Vokes EE
    Hematol Oncol Clin North Am; 1990 Dec; 4(6):1159-68. PubMed ID: 1704879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for non-small-cell lung cancer. Part 2: Advanced disease.
    Novello S; Le Chevalier T
    Oncology (Williston Park); 2003 Apr; 17(4):457-64, 469-71; discussion 471, 478-80, 483-4. PubMed ID: 12735143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic management of non-small-cell lung carcinoma (NSCLC) of stage III A].
    Mornex F
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S29-32. PubMed ID: 11924239
    [No Abstract]   [Full Text] [Related]  

  • 11. Implementation status and explanatory analysis of early advance care planning for Stage IV non-small cell lung cancer patients.
    Tokito T; Murakami H; Mori K; Osaka I; Takahashi T
    Jpn J Clin Oncol; 2015 Mar; 45(3):261-6. PubMed ID: 25480983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
    Goldman JW; Shi P; Reck M; Paz-Ares L; Koustenis A; Hurt KC
    Clin Lung Cancer; 2016 Jan; 17(1):80-4. PubMed ID: 26432508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.
    Rosenzweig KE; Movsas B; Bradley J; Gewanter RM; Gopal RS; Komaki RU; Kong FM; Lee HK; Feins RH; Langer CJ
    J Am Coll Radiol; 2009 Feb; 6(2):85-95. PubMed ID: 19179235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
    Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Lee SY
    Lung Cancer; 2015 Feb; 87(2):155-61. PubMed ID: 25488862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic treatment of non-small-cell lung cancer.
    Lal R; Enting D; Kristeleit H
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S375-7. PubMed ID: 21944021
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
    Santana-Davila R; Chow LQ
    Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of non-small cell lung cancer - where we are?].
    Milanowski J; Szmygin-Milanowska K
    Pneumonol Alergol Pol; 2013; 81(1):55-60. PubMed ID: 23258472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of advanced non-small-cell lung cancer (take home message).
    Pirker R
    Lung Cancer; 2004 Aug; 45 Suppl 2():S259-62. PubMed ID: 15552808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel in advanced non-small cell lung cancer.
    Wakelee H; Ramalingam S; Belani CP
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):13-24. PubMed ID: 15757434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.